RxSight (RXST) Price to Sales (2021 - 2026)

RxSight (RXST) has reported Price to Sales for 6 consecutive years, with 5.94 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 62.43% year-over-year to 5.94; the trailing twelve-month figure through Jun 2026 stood at 1.57 (down 56.56% YoY), and the FY2025 full-year result was 3.2, down 67.83% from the prior year.
• Price to Sales fell to 5.94 in Q2 2026 per RXST's latest filing, from 8.25 in the prior quarter.
• Across five years, Price to Sales topped out at 68.33 in Q2 2024 and bottomed at 5.94 in Q2 2026.
• Historically, Price to Sales has averaged 33.59 across 5 years, with a median of 33.32 in 2023.
• The sharpest annual moves came in 2023 and 2025: Price to Sales jumped 129.02% in 2023, then sank 78.4% in 2025.
• Over 5 years, Price to Sales stood at 22.26 in 2022, then soared by 129.02% to 50.98 in 2023, then sank by 32.21% to 34.56 in 2024, then sank by 61.87% to 13.18 in 2025, then tumbled by 54.92% to 5.94 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 5.94, 8.25, and 13.18 for Q2 2026, Q1 2026, and Q4 2025 respectively.